Medicare and Medicaid

• Insurance Coverage Mechanism and Access Barriers: Medicare and Medicaid function as intermediaries between patients and healthcare providers through contractual payment arrangements. When beneficiaries lack adequate insurance (whether due to coverage gaps, high deductibles, or state Medicaid non-expansion), they experience delayed or foregone care, leading to presentation with advanced disease. This mechanism directly drives worse health outcomes in vulnerable populations; for example, uninsured patients with acute myocardial infarction present with longer door-to-balloon times and higher mortality rates. The physiological consequence is disease progression in the absence of preventive or early intervention care.

• Reimbursement Rate Structure and Clinical Decision-Making: Medicare and Medicaid reimburse providers at rates substantially below commercial insurance and cost of care, creating financial pressure that influences clinical resource allocation. Lower reimbursement rates (Medicare pays approximately 40% less than commercial payers for identical services) incentivize providers to limit time per patient, reduce specialist referrals, and decrease adoption of expensive diagnostic technologies. This creates a system-level constraint on resource distribution that functionally determines which tests, procedures, and specialist consultations are pursued, thereby shaping clinical outcomes independent of disease biology.

• Coverage Determinations and Drug Access: Both programs maintain formularies and coverage policies that determine which medications are accessible to patients. When medications are not covered or require prior authorization, patients may delay therapy, use suboptimal alternative agents, or discontinue treatment altogether. This mechanism is particularly significant in chronic disease management; for example, if a potent statin is not on a Medicaid formulary but a less effective alternative is covered, population-level LDL control and cardiovascular outcomes differ predictably.

• Geographic and State-Level Variation in Coverage: Medicaid is administered at the state level with substantial variation in eligibility thresholds, covered services, and payment rates. This creates a "patchwork" system where a patient's clinical access to care depends on state of residence rather than clinical need alone. States that have not expanded Medicaid coverage under the Affordable Care Act create coverage gaps for individuals with incomes between 100-138% of the federal poverty level, affecting 2+ million Americans. The physiological consequence is that identical patients with identical diseases receive different access to preventive and therapeutic services based on geography.

• Prior Authorization and Utilization Review Processes: Both Medicare and Medicaid increasingly employ utilization review and prior authorization requirements that create delays in treatment initiation. These administrative barriers introduce latency between clinical decision and treatment implementation, potentially allowing disease progression during authorization periods. For time-sensitive conditions (sepsis, acute stroke, acute coronary syndromes), prior authorization delays can meaningfully impact outcomes, though emergency conditions typically bypass these requirements.

• Historical/Political Origins: Medicare and Medicaid were established in 1965 during President Lyndon B. Johnson's Great Society initiative in response to documented health disparities and lack of healthcare access among elderly and low-income Americans. The Political economy of American healthcare—including the influence of private insurance industry lobbying, physician groups, and state governments—shaped program design with inherent compromises that created coverage gaps and payment limitations. Understanding this context explains why the U.S. has universal coverage for elderly but not working-age adults, a historical accident rather than an evidence-based design.

• Expansion and Contraction Cycles: Medicare and Medicaid have undergone multiple expansions and cutbacks driven by federal budget cycles and political ideology rather than healthcare need. The Affordable Care Act (2010) expanded Medicaid eligibility to 138% of federal poverty level (optional for states after 2012 Supreme Court decision), but the decision to make expansion optional created a two-tiered system. States that declined expansion (predominantly in the South) have substantially higher uninsured rates and worse population health metrics—a policy choice rather than an epidemiologic necessity.

• Specific Vulnerable Populations: Certain groups face systematically worse coverage under these programs: (1) Undocumented immigrants are excluded from both Medicare and most Medicaid benefits (except emergency services and pregnancy-related care in some states), (2) Young adults earning just above Medicaid thresholds in non-expansion states fall into coverage gaps, (3) Rural residents have lower Medicaid expansion rates and face provider shortages, (4) Individuals with disabilities may face coverage restrictions despite being eligible. These represent structural risk factors for inadequate healthcare access.

• Pharmacy Benefit and Formulary Design: Both programs employ formulary restrictions, tiered copayments, and prior authorization requirements that vary significantly by program and state. Medicare Part D formularies are designed by individual insurance plans and differ substantially in drug coverage, creating "donut holes" (coverage gaps) where beneficiaries pay full cost after reaching initial coverage limit until out-of-pocket costs reach $7,050 (2024). Medicaid state formularies restrict access to newer, more expensive medications, forcing use of older agents that may be less effective or tolerable.

• Late-Stage Disease Presentation: Uninsured or underinsured patients (particularly in Medicaid non-expansion states) present with advanced disease that should have been detected or managed earlier. Patients with diabetes may present with diabetic ketoacidosis rather than with newly diagnosed diabetes in a clinic setting; cancer patients present with metastatic disease rather than localized malignancy; heart failure patients present with acute decompensation rather than at the stage of asymptomatic left ventricular dysfunction. This pattern reflects access barriers rather than disease biology—identical pathological processes, but delayed intervention.

• Medication Non-adherence Due to Cost: Patients on limited incomes demonstrate medication adherence patterns inversely correlated with out-of-pocket costs. Classic presentation includes: patient reports of taking medications "every other day" or "every few days" to stretch prescriptions, deliberate skipping of doses before refills become due, choosing between medications and food/utilities. This is physiologically manifest as inadequate disease control (persistent hypertension despite "being on medication," suboptimal A1C despite "taking diabetes pills") and increased acute complications (preventable acute coronary events in patients with known CAD who stopped statins due to cost).

• Diagnostic Test Avoidance: Patients delay or avoid recommended diagnostic testing due to coverage uncertainty or copayment burden. Cancer screening (mammography, colonoscopy) is deferred in Medicaid populations; cardiac workup is curtailed in cost-conscious patients. Clinically, this presents as detection at advanced stages when disease is both more aggressive biologically and more expensive to treat.

• Specialist Care Delays: Medicaid beneficiaries experience significantly longer wait times for specialist consultation and face geographic barriers if specialists do not accept Medicaid. A patient with newly diagnosed atrial fibrillation may wait weeks for cardiology evaluation in some Medicaid networks, during which untreated arrhythmia increases stroke risk; an infant with congenital heart disease may have delayed surgical referral.

• Emergency Department as Primary Care: Uninsured and underinsured patients disproportionately utilize emergency departments for non-emergent complaints because EDs cannot turn patients away due to inability to pay (EMTALA). ED presentations for conditions that would typically be managed in outpatient settings (uncomplicated UTI, mild asthma exacerbation, chronic pain management) represent a marker of inadequate outpatient access related to insurance coverage.

• Medication Interactions and Polypharmacy Issues: Patients juggling multiple insurance sources or coverage gaps may obtain medications from various sources (generic at one pharmacy due to coverage, brand-name elsewhere, drugs from international sources). This creates risk for unrecognized drug interactions, duplicate therapy, and adverse effects.

• Insurance Status Assessment and Coverage Verification: The clinical encounter must include explicit documentation of insurance type (Medicare Part A/B/D, Medicaid, dual-eligible, uninsured, etc.). Verification involves contacting the insurance plan directly to determine: (1) covered services for the patient's condition, (2) prior authorization requirements for planned tests/procedures, (3) formulary status of recommended medications, (4) out-of-pocket costs (copayment, coinsurance, deductible). This assessment directly impacts treatment planning—if a preferred medication is not covered, alternative agents or appeals processes must be identified before prescribing.

• Medicare Part Identification and Coverage Limitations:
• Part A (Hospital Insurance): Covers inpatient hospital stays, skilled nursing facility care, hospice, home health. Does NOT cover outpatient drugs, routine office visits, or preventive services (except annual wellness visit). Deductible applies per benefit period ($1,632 in 2024).
• Part B (Medical Insurance): Covers physician services, outpatient procedures, diagnostics, preventive services, mental health. Requires monthly premium (approximately $175/month in 2024) and applies 20% coinsurance after deductible ($240 in 2024).
• Part D (Prescription Drug Coverage): Voluntary prescription drug coverage through private plans. Coverage includes deductible ($585 in 2024), initial coverage period, coverage gap ("donut hole" where beneficiaries pay 25% of drug costs), and catastrophic coverage beyond out-of-pocket threshold. Formularies differ by plan.
• Medigap/Supplemental Insurance: Private supplemental insurance filling gaps in Medicare coverage, but not available to all and requires additional premium.
• Medicare Advantage (Part C): Alternative to original Medicare, offered by private insurers. All-in-one coverage replacing Parts A, B, and often D, but with network restrictions and prior authorization requirements.

• Medicaid Eligibility Determination: Medicaid eligibility varies substantially by state but generally includes:
• Income limits (typically 133-200% of federal poverty level, but varies by state and category)
• Categorical eligibility (disability, pregnancy, parent/caregiver status, children, elderly)
• Asset limits in some states (though many states have eliminated asset tests)
• Citizenship/immigration status (U.S. citizens and certain qualified immigrants eligible; undocumented immigrants excluded except emergency services)

• Coverage Gap Identification (Donut Hole): Patients on Medicare Part D should be assessed for whether they have entered the "donut hole"—the coverage gap where they pay 25% of drug costs after initial coverage limit ($11,000 in 2024) until out-of-pocket costs reach catastrophic threshold ($7,050 in 2024). Patients in the donut hole often stop taking medications, explaining apparent non-adherence. Extra Help/Low-Income Subsidy programs can reduce this burden for eligible beneficiaries.

• Prior Authorization Status: Before ordering expensive tests, procedures, or medications, explicit verification of prior authorization requirements is necessary. Obtaining authorization before care delivery prevents claim denials and patient financial liability. For example, advanced imaging (MRI, PET scan), newer cancer medications, and multiple specialist visits often require prior authorization in both Medicare Advantage and Medicaid plans.

• Dual-Eligible Status: Approximately 12 million beneficiaries are "dual-eligible"—eligible for both Medicare and Medicaid. This population is typically elderly or disabled with high medical complexity. Coverage determination requires checking both programs' rules, as Medicaid often serves as secondary payer covering gaps in Medicare.

• Screening for Social Determinants Related to Insurance: Validated screening tools should assess barriers: "Do you have difficulty affording medications? Do you skip doses or go without? Do you have trouble paying for healthcare visits? Do you have transportation to appointments?" Positive responses indicate insurance-related access barriers requiring intervention.

• Medication Selection Based on Formulary Status: When multiple medications are equally effective for a condition, first-line choice should prioritize drugs on the patient's formulary (lowest cost tier) to maximize adherence. For hypertension, generic ACE inhibitors or thiazide diuretics are typically tier-1 covered drugs on most Medicare and Medicaid plans; if preferred agents prove ineffective, newer/brand-name alternatives require prior authorization or patient cost-sharing that may exceed patient tolerance. For diabetes, older agents (metformin, sulfonylureas, insulin) are universally covered, while newer agents (GLP-1 agonists, SGLT-2 inhibitors) often require prior authorization and higher copayments, creating prescribing bias.

• Prior Authorization Strategies: Before prescribing medications or ordering tests, proactively determine authorization requirements and obtain approval in advance. For time-sensitive conditions, emergency authorization processes exist, but planned care should use routine authorization. Appeals processes exist for denials and should be pursued when clinical evidence supports a covered medication; many insurers approve on appeal after initial denial. For example, if a statin is not covered, documentation of statin intolerance with alternative agents failing usually results in coverage approval for the preferred agent.

• Generic/Biosimilar Selection: Recommend generic medications and biosimilars (once-available) to maximize coverage and minimize cost. Generic drugs are pharmacologically equivalent and covered identically to brand-name versions but at substantially lower cost, improving adherence. For biologic therapies (monoclonal antibodies, TNF inhibitors, etc.), biosimilars offer equivalent efficacy at lower cost when available, though some patients have coverage restrictions on biosimilar use.

• Medication Sampling and Assistance Programs: For medications with high cost or coverage barriers, utilize manufacturer patient assistance programs, which provide free or reduced-cost medication to uninsured/underinsured patients. Many institutions provide samples of short-term medications (antibiotics, short-course treatments) to uninsured patients to bridge gaps. Social work involvement can connect patients to pharmaceutical assistance programs specific to their medications.

• Stepwise Approach to Treatment Intensification: Rather than initiating combination therapy or high-dose regimens, use stepwise intensification aligned with insurance coverage. For example, in hypertension: initiate generic monotherapy (HCTZ, lisinopril, amlodipine), titrate to maximum dose, add second agent (generic), before considering newer agents requiring prior authorization. This approach respects insurance constraints while achieving clinical goals.

• Preventive Care Optimization Within Medicare/Medicaid: Maximize use of covered preventive services to prevent disease progression: Medicare Part B covers annual wellness visit, depression screening, cardiovascular disease screening, abdominal aortic aneurysm screening, cancer screenings (breast, colon, prostate), diabetes screening, bone density screening, glaucoma screening—all with no copayment. Medicaid covers preventive services similarly (varies by state). Actively recommending age/risk-appropriate screening to patients at no cost improves outcomes and reduces late-stage disease.

• Inpatient vs. Outpatient Treatment Considerations: Understand that Medicare Part A (hospital insurance) and Part B (outpatient insurance) have different coverage structures, which sometimes creates perverse incentives. Observation status (outpatient hospital care) has different cost-sharing than inpatient admission, affecting patient out-of-pocket costs. For Medicaid beneficiaries, inpatient psychiatric care may have different coverage than outpatient mental health services, influencing treatment setting selection.

• Medication Timing and Refill Strategies: Counsel patients on medication administration timing relative to food/other drugs to maximize efficacy and minimize side effects that might prompt discontinuation. For medications with potential adherence barriers, discuss specific strategies: (1) weekly pill organizers for complex regimens, (2) once-daily formulations when available to improve adherence, (3) 90-day supplies from mail-order pharmacies to reduce refill frequency and copayments. For Medicare beneficiaries entering the donut hole, discuss temporary use of lower-cost alternatives or discuss timing of expensive medications to minimize time in the gap.

• Care Coordination and Social Work Involvement: Integrate social work/case management to address insurance barriers, connect patients to covered services, identify

Who qualifies — the distinction examiners test

• **Medicare = age, Medicaid = *aid***: Medicare is purely federal and entitlement-based (≥65 years, or <65 with ≥24 months of Social Security Disability benefits, or with ESRD or ALS); Medicaid is joint federal–state and means-tested. Income is irrelevant to Medicare eligibility — a wealthy 70-year-old is covered.
• ESRD and ALS are the two disease-specific back doors into Medicare: a 30-year-old on maintenance hemodialysis is Medicare-eligible. This is the single most commonly tested association in the topic. ALS beneficiaries bypass the standard disability waiting period.

Part-by-part mnemonics

• **A = hospit*A*l, B = *B*ills (physician/outpatient), C = *C*hoice (Medicare Advantage, private plans), D = *D*rugs**: Part A is premium-free for most beneficiaries because it is financed by payroll tax; Parts B and D require premiums and are voluntary.
• Part B covers clinician-administered drugs and vaccines (influenza, pneumococcal, hepatitis B, COVID-19); Part D covers self-administered prescriptions including herpes zoster and Tdap vaccines. Per CMS, ACA-mandated USPSTF Grade A/B preventive services and the annual wellness visit carry no cost-sharing — but the wellness visit is a risk-assessment and planning encounter, not a head-to-toe physical.

The classic distractors

• Medicare does not pay for long-term custodial nursing home care — Medicaid is the dominant U.S. payer for long-term care and for a large share of U.S. births. Medicare Part A covers only time-limited skilled nursing facility care after a qualifying inpatient hospital stay.
• ***Observation status* is billed under Part B, not Part A**: a patient kept in observation, however long, does not accrue the inpatient days that trigger the SNF benefit, and faces different cost-sharing. Expect this as a discharge-planning stem.
• EMTALA obligates screening and stabilization regardless of insurance or ability to pay — the correct "next step" when a stem features an uninsured or undocumented patient in the ED is to evaluate and stabilize, never to transfer for payment reasons.

Policy point

• **ACA Medicaid expansion to 138% of the federal poverty level became optional after NFIB v. Sebelius (2012), creating the coverage gap described earlier. Dual-eligible** beneficiaries have Medicare as primary payer with Medicaid filling premiums, cost-sharing, and long-term care.